MEMOTEXT, a company specializing in developing and delivering personalized digital health interventions, today announced a collaboration with Massachusetts General Hospital (MGH) to create a text-messaging-based program that can help address the issue of medication adherence in children with attention deficit /hyperactivity disorder (ADHD). The collaboration aims to advance and make available to patients and families an evidence-based program developed by Joseph Biederman, MD, chief of clinical and research programs in pediatric psychopharmacology and his team at the MGH. MEMOTEXT will provide a comprehensive intervention using adaptive SMS/text messages to send reminders and educational messages to parents of children with ADHD about their child’s medication and treatment, how to handle daily activities, school, family relationships and ADHD in general as well as supportive messages. Parents can and will be encouraged to respond to messages to provide more information, which will help to customize their personal experience and make the program better by addressing their specific needs.
According to Biederman, studies have shown that at least 30 percent of children with ADHD do not renew their first prescription, and readily available technology may be a helpful tool in improving compliance. “Often parents may not fully understand the benefits and side effects of the medication, how the medication works or what they should expect from the treatment,” Biederman says. “In addition, physicians may have only a brief amount of time to spend with each patient and unfortunately cannot convey all the necessary and important information the child and the family need to feel comfortable with the treatment. Having information and reminders delivered to their mobile devices may help parents feel more reassured and confident in continuing with a treatment plan – and such compliance ultimately will help more children.”
With this program, regular educational messages are sent to parents during the first 30 days to provide them with information about ADHD and its treatment. By providing parents with the right information and tools, adherence to ADHD medication and treatment may greatly increase, which can help create a better overall treatment environment for children with ADHD and their families. “We are very excited to be working with such a prestigious hospital and clinical team,” says Amos Adler, MSc, president of MEMOTEXT. “There is tremendous potential for digital health technology to make a difference in the lives of people who suffer from mental health disorders such as ADHD. We hope this is the first step for a fruitful and innovative relationship between MEMOTEXT and MGH.”
MEMOTEXT Corp. improves outcomes for patients by ensuring they adhere to their treatment. With a proprietary, evidence-based self-learning algorithm and communications platform, MEMOTEXT integrates behavior change into the everyday lives of patients with personalized, secure, interactive voice, text, and mobile communications. Visit us at memotext.com
About Massachusetts General Hospital:
Massachusetts General Hospital is a leading medical center, which aims to deliver the very best health care in a safe, compassionate environment, to advance that care through innovative research and education, and to improve the health and well-being of the diverse communities it serves. To learn more visit http://www.massgeneral.org/default.aspx
About Dr. Joseph Biederman:
Dr. Joseph Biederman is the Chief of the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, and the Director of the Alan and Lorraine Bressler Clinical and Research Program for Autism Spectrum Disorders at the Massachusetts General Hospital, and a Professor of Psychiatry at Harvard Medical School. He is a leader in the field of ADHD and related disorders.